Lack of Robust Prognostic Biomarkers for Immunotherapy in Breast Cancer-Adverse Events-In Reply
JAMA Oncol
.
2019 Nov 1;5(11):1640.
doi: 10.1001/jamaoncol.2019.3605.
Authors
Sylvia Adams
1
,
Elizabeth A Mittendorf
2
3
Affiliations
1
Perlmutter Cancer Center, NYU School of Medicine, New York, New York.
2
Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
3
Breast Oncology Program, Dana-Farber Cancer Institute, Brigham and Women's Cancer Center, Boston, Massachusetts.
PMID:
31513254
DOI:
10.1001/jamaoncol.2019.3605
No abstract available